Blockade of angiotensin II type 2 receptor by XXXX inhibits osteogenic differentiation of @entity1 mesenchymal stem cells via inhibition of @entity3963 signaling.

@entity1 @entity917 @entity2178 @entity3963 @entity460 @entity729 @entity11083
Recent evidence indicates that the vasculature contains mesenchymal stem cells (MSCs). We hypothesized that @entity2178 ( @entity2178 ) type 2 receptors (AT2Rs) play a role in the osteogenesis of MSCs and may have a role in @entity729 . @entity1 MSCs were differentiated into osteoblasts. Expression of AT2R was significantly increased during osteogenesis, whereas the expression of @entity2178 type 1 receptors was not significantly changed. Incubation with the AT2R blocker @entity11083 with or without @entity2178 significantly inhibited @entity460 deposition, whereas type 1 receptor blocker @entity917 had no significant effect. @entity11083 inhibited @entity3963 ( @entity3963 ) phosphorylation in the osteogenic process, whereas @entity917 had no effect. Furthermore, @entity11083 combined with @entity2178 also inhibited acute @entity3963 phosphorylation in MSCs induced by insulin. In conclusion, AT2R is upregulated during osteogenesis. Blockade of AT2R inhibits osteogenesis and @entity3963 phosphorylation of @entity1 MSCs. These results provide a novel insight into the pathophysiology of @entity729 .
